Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Kathleen Nicholls und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Fabry Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amicus Therapeutics, Sanofi Australia Pty Ltd, Takeda Pharmaceuticals Australia Pty Ltd.
Abstract (Originalsprache)
Background
Disease‐specific therapy aims to improve symptoms, stabilise current disease and delay progression in patients with Fabry disease. In Australia, treatment access is subject to eligibility criteria initially established in 2004. Patients and their clinicians question why these criteria have remained unchanged despite significant progress in disease understanding.
Aims
Appraise the clinical quality of the Australian treatment access criteria.
Methods
The Fabry Australia Medical Advisory Committee ( N = 6) used the Appraisal of Guidelines for REsearch and Evaluation Global Rating Scale (AGREE II GRS) to assess the clinical quality of the current treatment eligibility criteria. They reviewed the literature, developed 17 clinical statements to help guide reforms of the eligibility criteria and achieved consensus (achievement of ≥75% agreement in the range 5–7 on a 7‐point Likert scale) through anonymous voting. The findings were applied to develop proposals for revised classification and treatment initiation criteria.
Results
The current treatment eligibility criteria underperformed on the AGREE II GRS. They are pragmatic but out‐of‐step with contemporary data. Consensus was achieved on all 17 proposed clinical statements. There was strong agreement to differentiate classical male Fabry patients to facilitate timelier access to Fabry‐specific treatment. There was also agreement on the value of adopting relevant organ involvement criteria in classical female patients and patients with non‐classical disease.
Conclusions
Australian access criteria are misaligned with current clinical evidence. The clinical statements and proposed classification and initiation criteria should prompt discussions to support more equitable access to treatment and better align Australian practice with contemporary evidence and international guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Academy of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Department of Genetic Medicine, Westmead Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Kathleen Nicholls, Charles Denaro, Michel Tchan, Carolyn Ellaway, Drago Bratkovic, Mark Thomas
Förderung
- Amicus Therapeutics
- Sanofi Australia Pty Ltd
- Takeda Pharmaceuticals Australia Pty Ltd
Zitieren
APA
Nicholls, K., Denaro, C., Tchan, M., Ellaway, C., Bratkovic, D., Campbell, S., Fookes, M., & Thomas, M. (2024). Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices. Internal Medicine Journal. https://doi.org/10.1111/imj.16327
Vancouver
Nicholls K, Denaro C, Tchan M, Ellaway C, Bratkovic D, Campbell S, et al. Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices. Internal Medicine Journal. 2024. doi:10.1111/imj.16327
BibTeX
@article{Nicholls2024,
author = {Nicholls, Kathleen and Denaro, Charles and Tchan, Michel and Ellaway, Carolyn and Bratkovic, Drago and Campbell, Sheridan and Fookes, Megan and Thomas, Mark},
title = {Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16327}
}
EUVIMED